Symons Julian A.

CIK 00018247271 companySOUTH SAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001824727

Recent Transactions

23 trades

Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2026-03-09+23,310→ 23,310 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2025-07-16+16,000→ 16,000 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2025-02-28+21,693→ 21,693 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2024-09-04+10,880→ 10,880 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2024-03-01+72,000→ 72,000 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2024-02-28+58,822→ 58,822 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2024-02-28+74,998→ 74,998 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2024-02-28+18,750→ 18,750 total
Disposition to Issuer
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2024-02-27−105,000→ 0 total
Disposition to Issuer
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2024-02-27−26,250→ 0 total
Disposition to Issuer
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2024-02-27−200,000→ 0 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2023-09-08+48,000→ 48,000 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2023-03-15+78,750→ 78,750 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2022-07-07+50,000→ 50,000 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2022-02-04+26,250→ 26,250 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2022-02-04+105,000→ 105,000 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2020-12-01+200,000→ 200,000 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+1,452→ 394,064 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series B-1 Preferred Stock
2020-10-20−3,394→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+13,671→ 389,218 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+3,394→ 392,612 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series B-2 Preferred Stock
2020-10-20−1,452→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series A Preferred Stock
2020-10-20−13,671→ 0 total

Companies

Aligos Therapeutics, Inc.
See Remarks
$ALGS

Recent Filings

Address

C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR

SOUTH SAN FRANCISCO, CA, 94080

View on SEC.gov